• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用编码突变型亨廷顿片段的慢病毒载体在原代神经元培养物中进行渐进性和选择性纹状体变性。

Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment.

作者信息

Zala Diana, Benchoua Alexandra, Brouillet Emmanuel, Perrin Valérie, Gaillard Marie-Claude, Zurn Anne D, Aebischer Patrick, Déglon Nicole

机构信息

Institute of Neurosciences, Swiss Federal Institute of Technology Lausanne, EPFL, 1015 Lausanne, Switzerland.

出版信息

Neurobiol Dis. 2005 Dec;20(3):785-98. doi: 10.1016/j.nbd.2005.05.017. Epub 2005 Jul 11.

DOI:10.1016/j.nbd.2005.05.017
PMID:16006135
Abstract

A lentiviral vector expressing a mutant huntingtin protein (htt171-82Q) was used to generate a chronic model of Huntington's disease (HD) in rat primary striatal cultures. In this model, the majority of neurons expressed the transgene so that Western blot analysis and flow cytometry measurement could complement immunohistological evaluation. Mutant huntingtin produced a slowly progressing pathology characterized after 1 month by the appearance of neuritic aggregates followed by intranuclear inclusions, morphological anomalies of neurites, loss of neurofilament 160, increased expression in stress response protein Hsp70, and later loss of neuronal markers such as NeuN and MAP-2. At 2 months post-infection, a significant increase in TUNEL-positive cells confirmed actual striatal cell loss. Interestingly, cortical cultures infected with the same vector showed no sign of neuronal dysfunction despite accumulation of numerous inclusions. We finally examined whether the trophic factors CNTF and BDNF that were found neuroprotective in acute HD models could prevent striatal degeneration in a chronic model. Results demonstrated that both agents were neuroprotective without modifying inclusion formation. The present study demonstrates that viral vectors coding for mutant htt provides an advantageous system for histological and biochemical analysis of HD pathogenesis in primary striatal cultures.

摘要

一种表达突变型亨廷顿蛋白(htt171 - 82Q)的慢病毒载体被用于在大鼠原代纹状体培养物中建立亨廷顿舞蹈病(HD)的慢性模型。在这个模型中,大多数神经元表达转基因,因此蛋白质免疫印迹分析和流式细胞术测量可以补充免疫组织学评估。突变型亨廷顿蛋白产生了一种进展缓慢的病理变化,1个月后表现为神经突聚集体的出现,随后是核内包涵体、神经突形态异常、神经丝160的丢失、应激反应蛋白Hsp70表达增加,以及后期神经元标志物如NeuN和MAP - 2的丢失。感染后2个月,TUNEL阳性细胞显著增加,证实了实际的纹状体细胞丢失。有趣的是,用相同载体感染的皮质培养物尽管积累了大量包涵体,但没有显示出神经元功能障碍的迹象。我们最终研究了在急性HD模型中发现具有神经保护作用的营养因子CNTF和BDNF是否能在慢性模型中预防纹状体变性。结果表明,这两种因子都具有神经保护作用,且不改变包涵体的形成。本研究表明,编码突变型htt的病毒载体为原代纹状体培养物中HD发病机制的组织学和生化分析提供了一个有利的系统。

相似文献

1
Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment.使用编码突变型亨廷顿片段的慢病毒载体在原代神经元培养物中进行渐进性和选择性纹状体变性。
Neurobiol Dis. 2005 Dec;20(3):785-98. doi: 10.1016/j.nbd.2005.05.017. Epub 2005 Jul 11.
2
Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration.基于腺病毒载体的亨廷顿病体外神经元细胞模型,具有人类疾病样的差异聚集和变性。
J Gene Med. 2012 Jul;14(7):468-81. doi: 10.1002/jgm.2641.
3
Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington's disease.热休克蛋白104和热休克蛋白27在基于慢病毒的亨廷顿舞蹈病大鼠模型中的神经保护作用
Mol Ther. 2007 May;15(5):903-11. doi: 10.1038/mt.sj.6300141. Epub 2007 Mar 20.
4
Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length.慢病毒介导的突变亨廷顿蛋白在大鼠纹状体中的传递会诱导一种由聚谷氨酰胺重复序列长度、亨廷顿蛋白表达水平和蛋白质长度所调节的选择性神经病理学变化。
J Neurosci. 2002 May 1;22(9):3473-83. doi: 10.1523/JNEUROSCI.22-09-03473.2002.
5
Early and reversible neuropathology induced by tetracycline-regulated lentiviral overexpression of mutant huntingtin in rat striatum.四环素调控的慢病毒在大鼠纹状体中过表达突变型亨廷顿蛋白所诱导的早期可逆性神经病理学变化
Hum Mol Genet. 2003 Nov 1;12(21):2827-36. doi: 10.1093/hmg/ddg305. Epub 2003 Sep 2.
6
Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into huntington's disease molecular pathogenesis.亨廷顿病分子发病机制的新见解来自于对亨廷顿蛋白水平、多聚谷氨酰胺长度、包含体形成和神经元死亡之间定量关系的研究。
J Neurosci. 2010 Aug 4;30(31):10541-50. doi: 10.1523/JNEUROSCI.0146-10.2010.
7
High efficiency adenovirus-mediated expression of truncated N-terminal huntingtin fragment (htt552) in primary rat astrocytes.高效腺病毒介导的截短型N端亨廷顿蛋白片段(htt552)在原代大鼠星形胶质细胞中的表达。
Acta Biochim Biophys Sin (Shanghai). 2009 Apr;41(4):325-34. doi: 10.1093/abbs/gmp021.
8
Inducing huntingtin inclusion formation in primary neuronal cell culture and in vivo by high-capacity adenoviral vectors expressing truncated and full-length huntingtin with polyglutamine expansion.通过表达带有聚谷氨酰胺扩增的截短型和全长亨廷顿蛋白的高容量腺病毒载体,在原代神经元细胞培养物和体内诱导亨廷顿蛋白包涵体形成。
J Gene Med. 2008 Mar;10(3):269-79. doi: 10.1002/jgm.1150.
9
Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice.亨廷顿蛋白聚集体相关的轴突退变是亨廷顿病小鼠的早期病理事件。
J Neurosci. 2001 Nov 1;21(21):8473-81. doi: 10.1523/JNEUROSCI.21-21-08473.2001.
10
Characterization of a rat model of Huntington's disease based on targeted expression of mutant huntingtin in the forebrain using adeno-associated viral vectors.基于腺相关病毒载体在大脑前脑靶向表达突变 huntingtin 建立亨廷顿病大鼠模型的特征。
Eur J Neurosci. 2012 Sep;36(6):2789-800. doi: 10.1111/j.1460-9568.2012.08193.x. Epub 2012 Jun 25.

引用本文的文献

1
Defective Mitochondrial Dynamics and Protein Degradation Pathways Underlie Cadmium-Induced Neurotoxicity and Cell Death in Huntington's Disease Striatal Cells.镉诱导亨廷顿病纹状体细胞神经毒性和细胞死亡的缺陷线粒体动力学和蛋白降解途径。
Int J Mol Sci. 2023 Apr 13;24(8):7178. doi: 10.3390/ijms24087178.
2
Advances in treatment of neurodegenerative diseases: Perspectives for combination of stem cells with neurotrophic factors.神经退行性疾病治疗进展:干细胞与神经营养因子联合应用的前景
World J Stem Cells. 2020 May 26;12(5):323-338. doi: 10.4252/wjsc.v12.i5.323.
3
The Evidence for the Spread and Seeding Capacities of the Mutant Huntingtin Protein in Systems and Their Therapeutic Implications.
突变型亨廷顿蛋白在各系统中的传播及播种能力的证据及其治疗意义
Front Neurosci. 2017 Nov 28;11:647. doi: 10.3389/fnins.2017.00647. eCollection 2017.
4
AMPK activation protects from neuronal dysfunction and vulnerability across nematode, cellular and mouse models of Huntington's disease.在亨廷顿舞蹈症的线虫、细胞和小鼠模型中,AMPK激活可保护神经元免受功能障碍和脆弱性影响。
Hum Mol Genet. 2016 Mar 15;25(6):1043-58. doi: 10.1093/hmg/ddv513. Epub 2015 Dec 17.
5
Amitriptyline improves motor function via enhanced neurotrophin signaling and mitochondrial functions in the murine N171-82Q Huntington disease model.在小鼠N171-82Q亨廷顿病模型中,阿米替林通过增强神经营养因子信号传导和线粒体功能来改善运动功能。
J Biol Chem. 2015 Jan 30;290(5):2728-43. doi: 10.1074/jbc.M114.588608. Epub 2014 Dec 11.
6
Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases.使用基因改造的间充质干细胞治疗神经退行性疾病。
Int J Mol Sci. 2014 Jan 23;15(2):1719-45. doi: 10.3390/ijms15021719.
7
A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease.一种强效且选择性的沉默调节蛋白1抑制剂可减轻亨廷顿舞蹈病多种动物和细胞模型中的病变。
Hum Mol Genet. 2014 Jun 1;23(11):2995-3007. doi: 10.1093/hmg/ddu010. Epub 2014 Jan 16.
8
Dose-dependent neuroprotection of VEGF₁₆₅ in Huntington's disease striatum.VEGF₁₆₅ 在亨廷顿病纹状体中具有剂量依赖性的神经保护作用。
Mol Ther. 2013 Oct;21(10):1862-75. doi: 10.1038/mt.2013.132. Epub 2013 Jun 25.
9
FACS array profiling identifies Ecto-5' nucleotidase as a striatopallidal neuron-specific gene involved in striatal-dependent learning.FACS 数组分析鉴定出外核苷酸磷酸酶 5' 作为一种纹状体依赖性学习中涉及纹状体投射神经元特异性的基因。
J Neurosci. 2013 May 15;33(20):8794-809. doi: 10.1523/JNEUROSCI.2989-12.2013.
10
MAP kinase phosphatase 1 (MKP-1/DUSP1) is neuroprotective in Huntington's disease via additive effects of JNK and p38 inhibition.丝裂原活化蛋白激酶磷酸酶 1(MKP-1/DUSP1)通过抑制 JNK 和 p38 的协同作用对亨廷顿病具有神经保护作用。
J Neurosci. 2013 Feb 6;33(6):2313-25. doi: 10.1523/JNEUROSCI.4965-11.2013.